Nureca Ltd Stock Analysis

BSE: 543264 | NSE: NURECA | Trading | Small Cap

BSE Share Price 26-Sep-2022 18:01
893.50 -59.95 (-6.29%)

DeciZen - Make an Informed Decision on Nureca Ltd.

Overall Rating

1. Quality

2. Valuation


3. Price Trend

Nureca Ltd. Price Chart

P/E Ratio (SA) :
Market Cap :
953.5 Cr.
52-wk low :
52-wk high :
Bole Toh?

1. Is Nureca Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Nureca Ltd is a good quality company.

2. Is Nureca Ltd undervalued or overvalued?

The key valuation ratios of Nureca Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Nureca Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Nureca Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Nureca Ltd.:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Nureca Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

ROCE % 67.7%59.3%56%50.5%24.5%-
Value Creation Index

Growth Parameters

Growth Parameters Colour Code Guide

Sales 0.60.799.4213256162
YoY Gr. Rt. %-23.7%13,520.6%114.6%19.8%-
Adj EPS 2.22.8911.646.644.75.3
YoY Gr. Rt. %-26.5%32226.6%-94.9%-4.1%-
BVPS (₹) 3.36.41,995.7163.3203.7199.9
Adj Net Profit 006.446.644.75
Cash Flow from Ops. 00.1-7.935.11.8-
Debt/CF from Ops. 00-1.200.6-


CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANA604.8%19.8%
Adj EPS NANA151.2%-4.1%
BVPS 00217.324.8
Share Price - - - -44.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Return on Equity % 60.454.48552.324.42.6
Op. Profit Mgn %
Net Profit Mgn %
Debt to Equity 000.700-
Working Cap Days 036062831300
Cash Conv. Cycle 01044138580

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 604.78%

Net Profit is growing at healthy rate in last 3 years 151.24%

Return on Equity has declined versus last 3 years average to 2.60%

Sales growth is not so good in last 4 quarters at -29.27%

Latest Financials - Nureca Ltd.

Standalone Consolidated
TTM EPS (₹) 5.3 4.6
TTM Sales (₹ Cr.) 162 162
BVPS (₹.) 199.9 199.1
Reserves (₹ Cr.) 190 189
P/BV 4.77 4.78
PE 180.27 205.40
From the Market
52 Week Low / High (₹) 939.35 / 2316.60
All Time Low / High (₹) 559.25 / 2316.60
Market Cap (₹ Cr.) 953
Equity (₹ Cr.) 10
Face Value (₹) 10
Industry PE 128.4

Management X-Ray of Nureca Ltd. :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Nureca Ltd.

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)


About Nureca Ltd

Nureca is a B2C company engaged in the business of home healthcare and wellness products, which offers quality, durability, functionality, usability and innovative designs. It enables its customers with tools to help them monitor chronic ailments and other diseases, to improve their lifestyle. It is a digital first company wherein it sells its products through online channel partners such as e-commerce players, distributors and retailer. Further, it also sells its products through its own website 

The company has most of the product lines supporting home health market in India, making it a one-stop solution provider. Dr Trust is a known for its innovative products in the market, and, with the segment showing significant potential for growth, the company is positioned to show significant growth.

The company has a diversified product portfolio, which primarily caters to home healthcare sector. It provides an improved product mix to its customers and their preferences thereby targeting a wider customer base. Its growth is further driven by its ability to make available an assortment of quality products under trusted brands built by the company.


Currently, the company classify its products portfolio under the following five categories such as:

  • Chronic Device Products - which includes products such as blood pressure monitors, pulse oximeters, thermometers, nebulizers, self monitoring glucose devices, humidifier and steamers.
  • Orthopedic Products - which includes rehabilitation products such as wheelchairs, walkers, lumbar and tailbone supports and physiotherapy electric massagers.
    Mother and Child Products - which includes products such as breast pumps, bottle sterilizers, bottle warmers, car seats and baby carry cots.
  • Nutrition Supplements - which includes products such as fish oil, multivitamins, probiotics, botin, apple cider and vinegar.
  • Lifestyle Products - which includes products such as smart scales, aroma diffusers and fitness tracker.

Key awards, recognitions and accreditations

  • 2020: The company received ISO 9001:2015 Certificate of Registration from Intertek Certification Limited for Management System, which is applicable to sales, services and warehousing of medical devices, consumer electronics, pharmaceutical and personal care products.
  • 2020: Appreciation Letter from Pharmaceuticals Export Promoter Council of India stating the company as a very dynamic and evolving medical devices company and has created a credible and leading brand ‘Dr. Trust’ which is now a household name in India.

Major events and milestones:

  • 2016: Online launch of Dr. Trust Brand.
  • 2017: Launched Dr. Physio brand in electric massager categories and Trumom brand in mother and child care categories.
  • 2017: Started three flex centres in Punjab, Karnataka and Uttar Pradesh.
  • 2018: The company became the wholly owned subsidiary of Nectar Biopharma Private Limited.
  • 2018: Added three flex centres in Chandigarh, Telangana and Maharashtra.
  • 2018: Secured warehouse drug license.
  • 2020 Transfer and vesting of Specified Undertaking (as defined under the Scheme) from Nectar Biopharma Private Limited to the company pursuant to the Scheme of Arrangement.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now